KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $132.7 million.

  • Vertex Pharmaceuticals' Net Cash Flow rose 12111.04% to $132.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $424.7 million, marking a year-over-year increase of 10737.65%. This contributed to the annual value of $424.7 million for FY2025, which is 10737.65% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Net Cash Flow is $132.7 million, which was up 12111.04% from -$30.1 million recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Net Cash Flow peaked at $1.3 billion during Q4 2022, and registered a low of -$4.6 billion during Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' Net Cash Flow averaged around -$46.7 million, with its median value being $228.5 million (2021).
  • In the last 5 years, Vertex Pharmaceuticals' Net Cash Flow skyrocketed by 55809.6% in 2022 and then crashed by 63973.81% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Net Cash Flow stood at $524.8 million in 2021, then surged by 146.61% to $1.3 billion in 2022, then tumbled by 159.63% to -$771.7 million in 2023, then rose by 18.54% to -$628.6 million in 2024, then skyrocketed by 121.11% to $132.7 million in 2025.
  • Its last three reported values are $132.7 million in Q4 2025, -$30.1 million for Q3 2025, and $239.4 million during Q2 2025.